Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Feb;75(2):e13896.
doi: 10.1111/ijcp.13896. Epub 2020 Dec 15.

Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19

İbrahim Halil Özdemir  1 , Bülent Özlek  2 , Mehmet Burak Özen  1 , Ramazan Gündüz  1 , Nurullah Çetin  3 , Ali Rıza Bilge  3
Affiliations
Observational Study

Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19

İbrahim Halil Özdemir et al. Int J Clin Pract. 2021 Feb.

Abstract

Background: Hydroxychloroquine (HCQ) and azithromycin (AZM) are widely used in off-label treatment of novel coronavirus disease (COVID-19). However, cardiac safety of these drugs is still controversial in COVID-19. Therefore, we aimed to evaluate association of HCQ or HCQ + AZM treatment regimens, corrected QT (QTc) interval and malignant ventricular arrhythmias in hospitalized patients.

Methods: This is a single-center, retrospective and observational study. All data were extracted from the electronic medical records. The initial and post-treatment mean QTc intervals were calculated and compared in patients with HCQ alone or HCQ + AZM therapy. Associated factors with QTc prolongation, the incidence of ventricular arrhythmia during treatment and in-hospital mortality because of ventricular arrhythmias were evaluated.

Results: Our cohort comprised 101 hospitalized COVID-19 patients (mean age of 49.60 ± 18 years, 54.4% men). HCQ + AZM combination therapy group (n = 56) was more likely to have comorbidities. After 5-days treatment, 19 (18.8%) patients had QTc prolongation, and significant increase in the QTc interval was observed in both two groups (P < .001). However, HCQ + AZM combination group had significantly higher ΔQTc compared to HCQ group (22.5 ± 18.4 vs 7.5 ± 15.3 ms, P < .001). All of 101 patients completed the 5-days treatment without interruption. Also, no malignant ventricular arrhythmia or death secondary to ventricular arrhythmia occurred during the treatment in both groups.

Conclusions: The present study revealed that although HCQ + AZM treatment was independently associated with QTc prolongation, none of patients experienced malignant ventricular arrhythmia or death during treatment. Further prospective studies are needed to determine the exact implications of these drugs on arrhythmias in patients with COVID-19.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Individual QTc intervals before and after treatment in HCQ + AZM group, only HCQ group, and all population. AZM, azithromycin; HCQ, hydroxychloroquine
FIGURE 2
FIGURE 2
The mean QTc intervals at admission and after 5‐days treatment in two treatment groups
FIGURE 3
FIGURE 3
Comparison of the mean QTc increase (ΔQTc) after treatment between HCQ + AZM and HCQ groups. AZM, azithromycin; HCQ, hydroxychloroquine
See this image and copyright information in PMC

References

    1. World Health Organization . Pneumonia of unknown cause—China. https://www.who.int/csr/don/05‐january‐2020‐pneumonia‐of‐unkown‐cause‐ch.... Accessed January 5, 2020.
    1. WHO . Novel Coronavirus–China; 2020. https://www.who.int/csr/don/12‐january‐2020‐novel‐coronavirus‐china/en/. Accessed February 1, 2020.
    1. Gao J, Tian Z, Yang X. Chloroquine phosphate has shown apparent efficacy in treatment of COVID‐19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72‐73. - PubMed
    1. Gautret P, Lagier J‐C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949. - PMC - PubMed
    1. Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006;44:173‐175. - PubMed

Publication types

MeSH terms